SCHEMBL18128752

SCHEMBL18128752

Nc1ncnc2nc(SC3CCCC3NC(=O)c3cccnc3)[nH]c12

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ LMNA P02545 2/20 0.39
▸ APEX1 P27695 1/20 0.38
▸ GRM5 P41594 1/20 0.38
▸ NUDT1 P36639 1/20 0.37
▸ TSHR P16473 2/20 0.37
▸ PKM P14618 1/20 0.37
▸ MAP4K4 O95819 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18128747 0.74 APEX1 (0.54) ALDH1A1HSD17B10LMNAAPEX1PKM
SCHEMBL10870623 0.74 HDAC1 (0.48) ALDH1A1LMNASMN1; SMN2HTT
SCHEMBL18128748 0.73 LMNA (0.48) ALDH1A1HSD17B10LMNAAPEX1NUDT1
SCHEMBL18128755 0.71 PKM (0.48) ALDH1A1HSD17B10LMNAAPEX1NUDT1
Niacinamide SCHEMBL8508206 0.68 F7 (0.54) ALDH1A1LMNAAPEX1NUDT1
Niacinamide SCHEMBL6371048 0.68 APEX1 (0.71) ALDH1A1HSD17B10LMNAAPEX1NUDT1
SCHEMBL7511254 0.67 GRM5 (0.54) ALDH1A1LMNAGRM5TSHRL3MBTL1
SCHEMBL18128744 0.67 PI4KA (0.46) ALDH1A1HSD17B10LMNAPKMMAP4K4
Niacinamide SCHEMBL3281893 0.67 ADORA2A (0.58) ALDH1A1LMNAAPEX1NUDT1PKM
SCHEMBL3427969 0.64 ALDH1A1 (0.70) ALDH1A1LMNAGRM5TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9926340-B2 NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-03-27 — — US disclosed
US-20160299141-A1 NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160299141-A1 NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS PARP11, PARP14, PARP15 ALDH1A1 1282/4885HSD17B10 2767/4885LMNA 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback